Navigation Links
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
Date:10/29/2010

s issued by Angiotech or to include such information in documents required to be filed with the applicable United States or Canadian securities regulatory authorities or otherwise make such information publicly available.

The projections and other forward looking financial information found herein were not, when made, and are not, historical facts but are forward looking statements about the objectives, strategies, financial conditions, results of operations and businesses of Angiotech and its subsidiaries and are subject to important risks, uncertainties and assumptions.  The forward looking statements and projections set out in this press release are, in the case of Angiotech's Base Medical Products and Proprietary Medical Products businesses, based upon Angiotech's reasonable estimates, assumptions and expectations about these businesses and the markets in which Angiotech operates at the time such information was prepared, or in the case of Angiotech's Royalty business, are derived based upon certain publicly available information, including analyst reports and other sources, regarding expectations for certain products, in particular for sales of paclitaxel-eluting stents by certain of our partners from which we derive or expect to derive royalty revenue pursuant to intellectual property licensing agreements with those partners.  In each case, such projections or forward looking statements are subject to significant business, economic, competitive and other uncertainties and contingencies (including those set out under the heading "Risk Factors" contained in Angiotech's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in Angiotech's most recent Form 10-Q and Management's Discussion and Analysis for the six months ended June 30, 2010), which are beyond Angiotech's or our partners' control.

In addition, forward looking statements reflect numerous assumptions by Angiotech and industry analysts with respect to fu
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
2. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
5. Angiotech Pharmaceuticals announces time change of conference call and webcast
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
8. Angiotech announces positive results from Bio-Seal(TM) clinical study
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
11. Angiotech announces date of annual general meeting of shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... Francis, WI (PRWEB) November 23, 2014 ... manufacturer and supplier of fine chemical ingredients to ... announced the launch of its new website, Apiscent.com. ... description of Apiscent Labs, clean design, easy navigation, ... that make Apiscent Labs stand out. ...
(Date:11/22/2014)... Prominent academics, leaders of the biopharmaceutical ... 3rd at Genetic Rx, a networking conference of ... place at the Joseph B. Martin Conference Center ... present and future of genetic medicines—including siRNA, ASOs, ... well as the treatment of patients with rare ...
(Date:11/22/2014)... Chicago, IL (PRWEB) November 21, 2014 ... technology competitors at the 2014 Emerging Medical Technologies Summit ... MedTech Innovator Awards. Widely regarded among Silicon Valley ... emerging medical device innovation, the win also positions Briteseed ... the MedTech Innovator competition in 2015 and compete with ...
(Date:11/22/2014)... , Nov. 21, 2014  The element of surprise ... diseases, i.e., they strike without warning. Until now, epidemiologists ... of a viral outbreak, resulting in suboptimal responses to ... currently. Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... now been removed because virus gene structural changes have ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Viruses' Advantage of Surprise is Lost 2
... Presentation Scheduled for Monday, March 17th at 11:30am ET, ... KERX ) today announced that I. Craig Henderson, ... Vice President,Medical Affairs, are scheduled to present at the ... The presentation, which will take place on Monday, ...
... Phase 2 Clinical Trial in ... ... today financial results for the year ended December,31, 2007, and highlighted the ... ), During 2007, the Company achieved the following corporate milestones:, ...
... for ... cars, phones, computers, ARGONNE, Ill., ... Laboratory and Toda Kogyo Corp. (Toda) of Japan have,reached a ... patented composite cathode materials for lithium-ion,batteries, which result in longer-lasting, ...
Cached Biology Technology:Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... PHOENIX, Ariz. Feb. 5, 2010 The Translational ... a strategic alliance and affiliation agreement with the Van ... capabilities of both non-profit institutes. TGen expects ... aimed at developing new tests and treatments for patient ...
... study of children in Ukraine has found that for ... care and the relationship between children and their caregivers ... their findings, the researchers highlight the importance of comprehensive ... changing caregivers, working schedules and providing training to enhance ...
... Mich. In an effort to eliminate the tropical ... researcher has been awarded $2 million to reformulate an ... their tracks. Charles Mackenzie, a professor of veterinary ... the funding via a larger $13 million grant the ...
Cached Biology News:TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3For HIV-infected children, quality of caregiver relationship is crucial 2MSU researcher awarded $2 million to tackle parasitic tropical diseases 2
... System, Professional Package Superior Protein Detection ... The ProXPRESS 2D Proteomic Imaging System is ... both proteomic and general life science research ... the use of all dyes in the ...
... single use spatulas have been designed to ... are for those interested in eliminating the ... Each spatula is individually packaged, RNase/DNase free, ... is a new product number, created to ...
... digital valve, just 8 mm in width. ... in a single glass-reinforced, PBT (Polybutylene Terephthalate) molded ... width. , Meets a range of pressure requirements ... Satisfies a 0.016 sccm leakage specification (0.2 sccm ...
... versatile system that simultaneously harvests and washes ... into a solid filter supports for analysis ... counter. The FilterMate is ideal for the ... cell proliferation, receptor binding, nucleic acid degradation, ...
Biology Products: